The recommendation for the sodium-glucose cotransporter-2 (SGLT-2) inhibitor is as monotherapy in adults with type II diabetes that cannot tolerate metformin, or as part of a dual therapy regimen in combination with metformin.
The treatment offers a new option for people with the disorder with a 20% lower acquisition cost than other SGLT-2 inhibitors, with the price of a once daily dose costing just £29.40 for 28 days’ treatment.
The decision is based on results from the VERTIS-MONO, VERTIS-MET and VERTIS-FACTORIAL trials, in which the drug showed significant change in HbA1c from baseline to week 26…
